Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBV Imaging to Assess HCC Perfusion Changes Potentiated by Intra-Arterial Nitroglycerin
NCT07682454Phase 2Not yet recruiting
- Sponsor
- University of California, San Francisco
- Start
- Dec 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nitroglycerin in hepatocellular carcinoma (HCC), sponsored by University of California, San Francisco. Primary endpoint: Proportion of Participants with >= 30% increase in Tumoral Blood Volume at Day 1. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
nitroglycerin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07682454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07682454.